Open AccessA Single Infusion of Zoledronate Prevents Bone Loss After Stroke
Author(s) -
Kenneth Poole,
N. Loveridge,
Collette Rose,
Elizabeth A. Warburton,
J. Reeve
Publication year - 2007
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.106.474262
Subject(s) - medicine , stroke (engine) , zoledronic acid , bone density conservation agents , osteoporosis , surgery , bone density , mechanical engineering , engineering
Stroke is a major risk factor for hip fracture. Patients with intermediate rather than severe or mild stroke deficits at the time of hospital discharge have the most fractures. This proof-of-concept study evaluated the efficacy of a single infusion of zoledronate, an intravenous bisphosphonate, in preserving hip bone density after stroke.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom